CN1185227C - 新化合物 - Google Patents

新化合物 Download PDF

Info

Publication number
CN1185227C
CN1185227C CNB00819064XA CN00819064A CN1185227C CN 1185227 C CN1185227 C CN 1185227C CN B00819064X A CNB00819064X A CN B00819064XA CN 00819064 A CN00819064 A CN 00819064A CN 1185227 C CN1185227 C CN 1185227C
Authority
CN
China
Prior art keywords
phenyl
diethyl
amino
compound
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB00819064XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1434818A (zh
Inventor
W·布朗
C·瓦尔波勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1434818A publication Critical patent/CN1434818A/zh
Application granted granted Critical
Publication of CN1185227C publication Critical patent/CN1185227C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB00819064XA 1999-12-20 2000-12-15 新化合物 Expired - Fee Related CN1185227C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904675A SE9904675D0 (sv) 1999-12-20 1999-12-20 Novel compounds
SE99046757 1999-12-20

Publications (2)

Publication Number Publication Date
CN1434818A CN1434818A (zh) 2003-08-06
CN1185227C true CN1185227C (zh) 2005-01-19

Family

ID=20418211

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB00819064XA Expired - Fee Related CN1185227C (zh) 1999-12-20 2000-12-15 新化合物

Country Status (32)

Country Link
US (1) US6875777B2 (OSRAM)
EP (1) EP1242406B1 (OSRAM)
JP (1) JP2003518136A (OSRAM)
KR (1) KR20020062351A (OSRAM)
CN (1) CN1185227C (OSRAM)
AT (1) ATE261957T1 (OSRAM)
AU (1) AU775648B2 (OSRAM)
BG (1) BG106807A (OSRAM)
BR (1) BR0016594A (OSRAM)
CA (1) CA2394864A1 (OSRAM)
CO (1) CO5271645A1 (OSRAM)
CZ (1) CZ20022123A3 (OSRAM)
DE (1) DE60009148T2 (OSRAM)
DK (1) DK1242406T3 (OSRAM)
EE (1) EE200200338A (OSRAM)
ES (1) ES2215786T3 (OSRAM)
HK (1) HK1048629B (OSRAM)
HU (1) HUP0300295A3 (OSRAM)
IL (1) IL150210A0 (OSRAM)
IS (1) IS6419A (OSRAM)
MX (1) MXPA02006064A (OSRAM)
NO (1) NO20022919L (OSRAM)
NZ (1) NZ519987A (OSRAM)
PL (1) PL355843A1 (OSRAM)
PT (1) PT1242406E (OSRAM)
RU (1) RU2002114346A (OSRAM)
SE (1) SE9904675D0 (OSRAM)
SK (1) SK8842002A3 (OSRAM)
TR (1) TR200401433T4 (OSRAM)
UA (1) UA72287C2 (OSRAM)
WO (1) WO2001046263A1 (OSRAM)
ZA (1) ZA200204257B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101771D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101770D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
SE0101769D0 (sv) 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US7229994B2 (en) 2001-05-18 2007-06-12 Astrazeneca Ab 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
SE0101773D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US8575169B2 (en) 2001-10-29 2013-11-05 Versi Group, Llc Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
EP1450807B1 (en) * 2001-10-29 2013-12-25 Versi Group, LLC Method of treating depression with delta receptor agonist compounds
US8476280B2 (en) * 2002-05-09 2013-07-02 Versi Group, Llc Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
CN101128447A (zh) * 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
EP4333821A4 (en) * 2021-05-04 2025-07-09 Texas A & M Univ Sys SARS-COV-2 INHIBITORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091096A (en) 1976-03-19 1978-05-23 Eli Lilly And Company Dinitroanilines for the control of phytopathogens
EG12406A (en) 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
SE441448B (sv) 1977-05-23 1985-10-07 Pfizer Sett att framstella hexahydro-gamma-karbolinforeningar
DE3200304A1 (de) 1981-01-16 1982-08-26 Sandoz-Patent-GmbH, 7850 Lörrach 3-aminopropoxyaryl-derivate, ihre herstellung und sie enthaltende arzneimittel
DE3563964D1 (en) 1984-10-16 1988-09-01 Synthelabo Piperidine derivatives, their preparation and their therapeutical application
KR940003491B1 (ko) 1989-08-10 1994-04-23 리히터 게데온 베기에스제티 기아르 알.티 4,4-이중 치환된 피페리딘 유도체와 그 제조방법 및 상기 화합물을 함유하는 약제학적 조성물
YU150489A (sh) 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
AU2009799A (en) 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
AU756983B2 (en) 1998-03-10 2003-01-30 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
US6436959B1 (en) * 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides

Also Published As

Publication number Publication date
BG106807A (en) 2003-03-31
CZ20022123A3 (cs) 2002-11-13
RU2002114346A (ru) 2004-01-20
MXPA02006064A (es) 2002-12-05
NZ519987A (en) 2004-04-30
IS6419A (is) 2002-06-12
BR0016594A (pt) 2002-09-10
AU775648B2 (en) 2004-08-12
EP1242406B1 (en) 2004-03-17
JP2003518136A (ja) 2003-06-03
ES2215786T3 (es) 2004-10-16
IL150210A0 (en) 2002-12-01
TR200401433T4 (tr) 2004-09-21
PT1242406E (pt) 2004-07-30
CN1434818A (zh) 2003-08-06
SK8842002A3 (en) 2003-05-02
NO20022919L (no) 2002-08-02
DE60009148T2 (de) 2005-02-03
CO5271645A1 (es) 2003-04-30
DK1242406T3 (da) 2004-06-28
DE60009148D1 (de) 2004-04-22
US6875777B2 (en) 2005-04-05
AU2564401A (en) 2001-07-03
CA2394864A1 (en) 2001-06-28
NO20022919D0 (no) 2002-06-18
WO2001046263A1 (en) 2001-06-28
US20030036552A1 (en) 2003-02-20
ZA200204257B (en) 2003-08-28
KR20020062351A (ko) 2002-07-25
HK1048629A1 (en) 2003-04-11
HK1048629B (en) 2004-12-03
PL355843A1 (en) 2004-05-17
HUP0300295A3 (en) 2006-01-30
UA72287C2 (uk) 2005-02-15
HUP0300295A2 (hu) 2003-06-28
EE200200338A (et) 2003-10-15
ATE261957T1 (de) 2004-04-15
SE9904675D0 (sv) 1999-12-20
EP1242406A1 (en) 2002-09-25

Similar Documents

Publication Publication Date Title
CN1146540C (zh) 具有镇痛作用的新化合物及其用途
CN1056605C (zh) 作为人速激肽ⅲ受体的选择性拮抗剂的化合物及其用途
CN1202093C (zh) 取代的杂环化合物
CN1035944C (zh) 3-氨基哌啶衍生物及有关的含氮杂环化合物的制备方法
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1185228C (zh) 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物
CN1185227C (zh) 新化合物
CN1184471A (zh) 氨基噻唑衍生物、含有它们的药物及制备该化合物的中间体
CN1777584A (zh) 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CN1681801A (zh) 喹啉基丙基哌啶衍生物以及其作为抗微生物剂的应用
CN1065455A (zh) 哌啶衍生物
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1527820A (zh) 4-(苯基-(哌嗪基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑症或胃肠病中的应用
CN88102191A (zh) 哌啶类类鸦片物质拮抗剂
CN1225465C (zh) 新化合物
CN1735595A (zh) 取代的烷基酰氨基哌啶
CN1039415A (zh) 新的1，3-二取代哌啶衍生物的制备方法
CN1930158A (zh) 新季铵化的奎宁环酯
CN1471520A (zh) 氨基烷氧基苯甲酰基-苯并呋喃类或苯并噻吩类,它们的制备方法以及含有它们的组合物
CN1711252A (zh) 4－(苯基－哌嗪基－甲基)苯甲酰胺衍生物及其在治疗疼痛或胃肠疾病中的用途
CN1182134C (zh) 用于治疗疼痛的喹啉基-亚哌啶-4-基-甲基-苯甲酰胺衍生物
CN1768052A (zh) 取代的吡唑化合物
CN1620452A (zh) 3,4－二氢－1h－异喹啉－2－基－衍生物
CN1926122A (zh) 二芳基甲基哌嗪衍生物及其制备并用途
CN1273463C (zh) (1－苯甲酰甲基－3－苯基－3－哌啶基乙基)哌啶衍生物,制备它们的方法以及包含它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee